Relationship of ambulatory blood pressure and the heart rate profile with renal function parameters in hypertensive patients with chronic kidney disease

Clinical and Experimental Hypertension

Volumn 34, Issue 4, 2012, Pages 264-269

  Kanaoka, Tomohiko ^a   Tamura, Kouichi ^a   Ohsawa, Masato ^a   Yanagi, Mai ^a   Haku, Sona ^a   Wakui, Hiromichi ^a   Maeda, Akinobu ^a   Dejima, Toru ^a   Azushima, Kengo ^a   Mitsuhashi, Hiroshi ^a   Okano, Yasuko ^a   Fujikawa, Tetsuya ^a   Toya, Yoshiyuki ^a   Mizushima, Shunsaku ^a   Tochikubo, Osamu ^a   Umemura, Satoshi ^a  

^a YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

ambulatory BP monitoring; arterial stiffness; central BP; chronic kidney disease; HR variability; hypertension; oxidative stress

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; HEMOGLOBIN A1C; PENTOSIDINE;

AGED; ARTERIAL STIFFNESS; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; CIRCADIAN RHYTHM; CLINICAL ARTICLE; DETERIORATION; FEMALE; GLOMERULUS FILTRATION RATE; HEART RATE; HEART RATE VARIABILITY; HEMODYNAMICS; HOSPITAL PATIENT; HUMAN; HYPERTENSION; KIDNEY FUNCTION; MALE; SYSTOLIC BLOOD PRESSURE; URINE ALBUMIN EXCRETION RATE;

AGED; ALBUMINURIA; ANKLE BRACHIAL INDEX; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CROSS-SECTIONAL STUDIES; FEMALE; GLOMERULAR FILTRATION RATE; HEART RATE; HUMANS; HYPERTENSION, RENAL; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC; VASCULAR STIFFNESS;

EID: 84862229811     PISSN: 10641963     EISSN: 15256006     Source Type: Journal    
DOI: 10.3109/10641963.2012.681082     Document Type: Article

References (50)

1. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995-1003. (Pubitemid 34286536)
2. Casas JP, Chua W, Loukogeorgakis S, et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 2005; 366:2026-2033. (Pubitemid 41773378)
3. Spallone V, Bernardi L, Ricordi L, et al. Relationship between the circadian rhythms of blood pressure and sympathovagal balance in diabetic autonomic neuropathy. Diabetes 1993; 42:1745-1752. (Pubitemid 23346411)
4. Nakano S, Fukuda M, Hotta F, et al. Reversed circadian blood pressure rhythm is associated with occurrences of both fatal and nonfatal vascular events in NIDDM subjects. Diabetes 1998; 47:1501-1506. (Pubitemid 28396956)
5. Sturrock ND, George E, Pound N, Stevenson J, PeckGM, Sowter H. Non-dipping circadian blood pressure and renal impairment are associated with increased mortality in diabetes mellitus. Diabetes Med 2000; 17:360-364. (Pubitemid 30353800)
6. Palmas W, Pickering TG, Teresi J, et al. Ambulatory blood pressure monitoring and all-cause mortality in elderly people with diabetes mellitus. Hypertension 2009; 53:120-127.
7. Williams B, Lacy PS, Thom SM, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006; 113: 1213-1225.
8. Wang KL, Cheng HM, Chuang SY, et al. Central or peripheral systolic or pulse pressure: which best relates to target organs and future mortality? J Hypertens 2009; 27:461-467.
9. WangKL,ChengHM, Sung SH, et al.Wave reflection and arterial stiffness in the prediction of 15-year all-cause and cardiovascular mortalities: a community-based study. Hypertension 2010; 55:799-805.
10. Gomez-Marcos MA, Recio-Rodriguez JI, Rodriguez-Sanchez E, et al. Central blood pressure and pulse wave velocity: relationship to target organ damage and cardiovascular morbidity-mortality in diabetic patients or metabolic syndrome. An observational prospective study. LOD-DIABETES study protocol. BMC Public Health 2010; 10:143.
11. Vlachopoulos C, Aznaouridis K, O'Rourke MF, Safar ME, Baou K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with central haemodynamics: a systematic review and meta-analysis. Eur Heart J 2010; 31:1865-1871.
12. Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol 2010; 55:1318-1327.
13. Huang CM, Wang KL, Cheng HM, et al. Central versus ambulatory blood pressure in the prediction of all-cause and cardiovascular mortalities. J Hypertens 2011; 29:454-459.
14. Tamura K, Tsurumi Y, Sakai M, et al. A possible relationship of nocturnal blood pressure variability with coronary artery disease in diabetic nephropathy. Clin Exp Hypertens 2007; 29:31-42.
15. Ozawa M, Tamura K, Okano Y, et al. Identification of an increased short-term blood pressure variability on ambulatory blood pressure monitoring as a coronary risk factor in diabetic hypertensives. Clin Exp Hypertens 2009; 31:259-270.
16. Kanaoka T, Tamura K, Moriya T, et al. Effects of multiple factorial intervention on ambulatory BP profile and renal function in hypertensive type 2 diabetic patients with overt nephropathy - a pilot study. Clin Exp Hypertens 2011; 33:255-263.
17. Tamura K, Yamauchi J, Tsurumi-Ikeya Y, et al. Ambulatory blood pressure and heart rate in hypertensives with renal failure: comparison between diabetic nephropathy and non-diabetic glomerulopathy. Clin Exp Hypertens 2008; 30:33-43. (Pubitemid 351157006)
18. Kikuya M, Hozawa A, Ohokubo T, et al. Prognostic significance of blood pressure and heart rate variabilities: the Ohasama study. Hypertension 2000; 36:901-906.
19. Sander D, Kukla C, Klingelhofer J, Winbeck K, Conrad B. Relationship between circadian blood pressure patterns and progression of early carotid atherosclerosis: a 3-year follow-up study. Circulation 2000; 102:1536-1541.
20. Eto M, Toba K, Akishita M, et al. Impact of blood pressure variability on cardiovascular events in elderly patients with hypertension. Hypertens Res 2005; 28:1-7. (Pubitemid 40584956)
21. Mitsuhashi H, Tamura K, Yamauchi J, et al. Effect of losartan on ambulatory short-term blood pressure variability and cardiovascular remodeling in hypertensive patients on hemodialysis. Atherosclerosis 2009; 207:186-190.
22. Masuda S, Tamura K, Wakui H, et al. Effects of angiotensin II type 1 receptor blocker on ambulatory blood pressure variability in hypertensive patients with overt diabetic nephropathy. Hypertens Res 2009; 32:950-955.
23. Ozawa M, Tamura K, Okano Y, et al. Blood pressure variability as well as blood pressure level is important for left ventricular hypertrophy and brachial-ankle pulse wave velocity in hypertensives. Clin Exp Hypertens 2009; 31:669-679.
24. Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009; 53:982-992.
25. Takazawa K, Kobayashi H, Shindo N, Tanaka N, Yamashina A. Relationship between radial and central arterial pulse wave and evaluation of central aortic pressure using the radial arterial pulse wave. Hypertens Res 2007; 30:219-228. (Pubitemid 46605446)
26. Kips JG, Schutte AE, Vermeersch SJ, et al. Comparison of central pressure estimates obtained from SphygmoCor, Omron HEM-9000AI and carotid applanation tonometry. J Hypertens 2011; 29:1115-1120.
27. Rezai MR, Goudot G, Winters C, Finn JD, Wu FC, Cruickshank JK. Calibration mode influences central blood pressure differences between SphygmoCor and two newer devices, the Arteriograph and Omron HEM-9000. Hypertens Res 2011; 34:1046-1051.
28. Tomiyama H, Odaira M, Matsumoto C, et al. Effects of moderate-to-severe impairment of the estimated glomerular filtration rate and of proteinuria on the central hemodynamicsand arterial stiffness in middle-aged healthy Japanese men. Int J Nephrol 2011; 2011:427-471.
29. Yamashina A, Tomiyama H, Takeda K, et al. Validity, reproducibility, and clinical significance of noninvasive brachial-ankle pulse wave velocity measurement. Hypertens Res 2002; 25:359-364. (Pubitemid 34752554)
30. Takebayashi K, Matsutomo R, Matsumoto S, et al. Relationships between heart rate variability and urinary albumin excretion in patients with type 2 diabetes. Am J Med Sci 2006; 331:72-78.
31. Boulatov VA, Stenehjem A, Os I. Association between albumin: creatinine ratio and 24-hour ambulatory blood pressure in essential hypertension. Am J Hypertens 2001; 14:338-344.
32. Palmas W,Moran A, Pickering T, et al. Ambulatory pulse pressure and progression of urinary albumin excretion in older patients with type 2 diabetes mellitus. Hypertension 2006; 48:301-308. (Pubitemid 44309827)
33. Marcovecchio ML, Dalton RN, Schwarze CP, et al. Ambulatory blood pressure measurements are related to albumin excretion and are predictive for risk of microalbuminuria in young people with type 1 diabetes. Diabetologia 2009; 52:1173-1181.
34. Nishimura M, Uzu T, Fujii T, Kimura G. Disturbed circadian rhythm of urinary albumin excretion in non-dipper type of essential hypertension. Am J Nephrol 2002; 22:455-462. (Pubitemid 36158503)
35. Palmas W, Pickering T, Teresi J, et al. Nocturnal blood pressure elevation predicts progression of albuminuria in elderly people with type 2 diabetes. J Clin Hypertens (Greenwich) 2008; 10:12-20.
36. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359:2417-2428.
37. Matsushita K, van der Velde M, Astor BC, et al. Association of estimated glomerular filtration rate and albuminuria with allcause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010; 375:2073-2081.
38. Bakris GL, Sarafidis PA, Weir MR, et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 2010; 375:1173-1181.
39. Fukuta H, Hayano J, Ishihara S, et al. Prognostic value of heart rate variability in patients with end-stage renal disease on chronic haemodialysis. Nephrol Dial Transplant 2003; 18:318-325. (Pubitemid 36181683)
40. Oikawa K, Ishihara R, Maeda T, et al. Prognostic value of heart rate variability in patients with renal failure on hemodialysis. Int J Cardiol 2009; 131:370-377.
41. Pop-Busui R, Evans GW, Gerstein HC, et al. Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care 2010; 33:1578-1584.
42. Chandra P, Sands RL, Gillespie BW, et al. Predictors of heart rate variability and its prognostic significance in chronic kidney disease. Nephrol Dial Transplant 2012; 27:700-709.
43. Hou FF, Ren H, Owen WF Jr, et al. Enhanced expression of receptor for advanced glycation end products in chronic kidney disease. J Am Soc Nephrol 2004; 15:1889-1896. (Pubitemid 38822069)
44. Candido R, Forbes JM, Thomas MC, et al. A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. Circ Res 2003; 92:785-792. (Pubitemid 36457644)
45. Jandeleit-Dahm K, Lassila M, Allen T. Advanced glycation end products in diabetes-associated atherosclerosis and renal disease: interventional studies. Ann N Y Acad Sci 2005; 1043:759-766. (Pubitemid 41123970)
46. Miyata T, Ueda Y, Horie K, et al. Renal catabolism of advanced glycation end products: the fate of pentosidine. Kidney Int 1998; 53:416-422.
47. Piroddi M, Palazzetti I, QuintalianiG, et al. Circulating levels and dietary intake of the advanced glycation end-product marker carboxymethyl lysine in chronic kidney disease patients on conservative predialysis therapy: a pilot study. J Ren Nutr 2011; 21:329-339.
48. Ohishi M, Tatara Y, Ito N, et al. The combination of chronic kidney disease and increased arterial stiffness is a predictor for stroke and cardiovascular disease in hypertensive patients. Hypertens Res 2011; 34:1209-1215.
49. Moriya T, Tanaka K, Hosaka T, Hirasawa Y, Fujita Y. Renal structure as an indicator for development of albuminuria in normo- and microalbuminuric type 2 diabetic patients. Diabetes Res Clin Pract 2008; 82:298-304.
50. Ohnuki K, Umezono T, Abe M, et al. Expression of transcription factor Snai1 and tubulointerstitial fibrosis in progressive nephropathy. J Nephrol 2012; 25:233-239.